Skip to main content
Log in

BRCA1- und BRCA2-assoziierte Mammakarzinome

BRCA1- and BRCA2- associated breast carcinomas

  • Aktuelles aus der Forschung in der Pathologie
  • Published:
Der Pathologe Aims and scope Submit manuscript

Zusammenfassung

Mammakarzinome mit einem genetischen BRCA1-/BRCA2-Hintergrund unterscheiden sich voneinander und von den sporadischen Tumoren, ohne dass jedoch ein spezifischer pathologischer Surrogatmarker existiert. Im Folgenden werden die in Deutschland erhaltenen Befunde eines Referenzzentrums präsentiert. BRCA1-assoziierte Karzinome sind in der Mehrzahl schlecht differenziert [Grad (G)3 der Union Internationale Contre le Cancer], „triple“-negativ, hoch proliferationsaktiv (medianes Ki-67 55%) und nur sehr selten von einer lobulären intraepithelialen Neoplasie begleitet. BRCA2-bedingte Karzinome sind deutlich seltener und ähneln eher sporadischen Fällen; auch hier liegt eine gesteigerte Proliferationsaktivität vor, und eine Her2-Überexpression kommt kaum vor.

Abstract

Breast cancers with a genetic BRCA1-/BRCA2 background differ from each other and sporadic cases. A specific pathological surrogate marker, however, does not exist. In this study the results of a German reference centre are reported. BRCA1 associated cancers are predominantly high grade (G3), triple negative, highly proliferative (median Ki-67 55%) and only exceptionally accompanied by lobular intraepithelial neoplasia. Cancers with a BRCA2 germ line mutation are less frequent and resemble sporadic cases with a comparably higher proliferative activity and a lack of Her2 overexpression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Breast Cancer Linkage Consortium (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1-or BRCA2-mutations and sporadic cases. Lancet 349:1505–1510

    Article  Google Scholar 

  2. Byrski T, Huzarski T, Dent R et al (2009) Response to neoadjuvant therapy with cisplatin in BRCA1--positive breast cancer patients. Breast Cancer Res Treat 115:359–363

    Article  CAS  PubMed  Google Scholar 

  3. Houlston RS, Peto J (2004) The search for low-penetrance cancer susceptibility alleles. Onocgene 23:6471–6476

    Article  CAS  Google Scholar 

  4. Lakhani SR, Jacquemier J, Sloane JP et al (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1-and BRCA2-mutations. J Natl Cancer Inst 90:1138–1145

    Article  CAS  PubMed  Google Scholar 

  5. Lakhani SR, Van De Vijver MJ, Jacquemier J et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1-and BRCA2-. J Clin Oncol 20:2310–2318

    Article  CAS  PubMed  Google Scholar 

  6. Ripperger T, Gadzicki D, Meindl A, Schlegelberger B (2009) Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet 17:722–731

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H.H. Kreipe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ahrens, P., Kreipe, H. BRCA1- und BRCA2-assoziierte Mammakarzinome. Pathologe 30 (Suppl 2), 207–209 (2009). https://doi.org/10.1007/s00292-009-1223-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00292-009-1223-3

Schlüsselwörter

Keywords

Navigation